Loading...
At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2017), held June 3 to 7 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Associate Editor Robert Dreicer, MD, MS, FACP, FASCO, reviews key presentations on new genitourinary cancer therapies. All meeting abstracts can be viewed in the ASCO meeting library).
Until recently, therapeutic options for cisplatin-ineligible patients with advanced urothelial cancer were limited. Carboplatin-based chemotherapy has been considered a standard of care, and recently ate…